Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
81.18
+2.84 (3.63%)
At close: Jun 26, 2026, 4:00 PM EDT
82.01
+0.83 (1.02%)
After-hours: Jun 26, 2026, 7:36 PM EDT
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Ionis Pharmaceuticals stock have an average target of 103.67, with a low estimate of 75 and a high estimate of 130. The average target predicts an increase of 27.70% from the current stock price of 81.18.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock from 24 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 11 | 12 | 12 |
| Buy | 6 | 6 | 6 | 8 | 9 | 9 |
| Hold | 6 | 6 | 6 | 5 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 22 | 22 | 24 | 26 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $115 | Buy | Maintains | $115 | +41.66% | Jun 26, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $80 → $90 | Buy | Reiterates | $80 → $90 | +10.86% | Jun 25, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $110 | Buy | Maintains | $110 | +35.50% | Jun 25, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $130 | Buy | Reiterates | $130 | +60.14% | Jun 25, 2026 |
Unknown Analyst Wells Fargo No rating | Wells Fargo | Buy Maintains $100 | Buy | Maintains | $100 | +23.18% | Jun 25, 2026 |
Financial Forecast
Revenue This Year
893.40M
from 943.71M
Decreased by -5.33%
Revenue Next Year
1.51B
from 893.40M
Increased by 68.46%
EPS This Year
-2.69
from -1.54
EPS Next Year
-0.61
from -2.69
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 947.0M | 2.0B | |
| Avg | 893.4M | 1.5B | |
| Low | 881.7M | 1.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.3% | 127.5% | |
| Avg | -5.3% | 68.5% | |
| Low | -6.6% | 41.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.59 | 0.26 | |
| Avg | -2.69 | -0.61 | |
| Low | -2.79 | -2.21 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.